Immunocore to present at upcoming investor conferences
Immunocore (Nasdaq: IMCR) announced that management will participate in investor conferences on November 17 and 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunocore (Nasdaq: IMCR) announced that management will participate in investor conferences on November 17 and 18, 2026. The UBS Global Biopharma Conference fireside chat is scheduled for November 17 at 3:20 p.m. GMT. Management will hold one-on-one and small group meetings at the Jefferies London Global Healthcare Conference on November 18. The presentation will be webcast live through the company’s investor website, with a replay available for a limited time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
UBS Global Biopharma Conference 2026
Fireside Chat: Tuesday, November 17, 2026, at 3:20 p.m. GMT
Jefferies London Global Healthcare Conference
1x1 and small group meetings: Wednesday, November 18, 2026
The presentation will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in 39 countries, including the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Vice President Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore
Ryan Baker, Vice President of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
